News coverage about CTI BioPharma (NASDAQ:CTIC) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CTI BioPharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.7648684045194 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several analysts recently issued reports on the company. Jefferies Group assumed coverage on CTI BioPharma in a research report on Tuesday, September 12th. They set a “buy” rating and a $7.50 target price for the company. ValuEngine cut CTI BioPharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th.

Shares of CTI BioPharma (NASDAQ CTIC) opened at $2.53 on Wednesday. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26. CTI BioPharma has a 1 year low of $2.45 and a 1 year high of $6.48.

CTI BioPharma (NASDAQ:CTIC) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. CTI BioPharma had a negative return on equity of 209.67% and a negative net margin of 96.91%. The firm had revenue of $1.71 million during the quarter, compared to analysts’ expectations of $0.30 million. equities analysts predict that CTI BioPharma will post -1.2 earnings per share for the current fiscal year.

In related news, Director Richard L. Love sold 14,600 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $3.21, for a total transaction of $46,866.00. Following the completion of the sale, the director now owns 84,318 shares in the company, valued at $270,660.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.16% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect CTI BioPharma (CTIC) Share Price” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-cti-biopharma-ctic-share-price/1774232.html.

About CTI BioPharma

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Insider Buying and Selling by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.